NCT00475878

SSRI and Buprenorphine

Antidepressants During Office-Based Buprenorphine

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 147 (actual)
• Sponsor: Butler Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.

Detailed description

Participants interested in receiving Buprenorphine will be offered the opportunity to enroll in this study. Enrolled study participants will complete interviews at baseline and again every two weeks for a total of 8 interviews over 3 months. In this double-blind randomized controlled trial, participants will either receive a placebo or escitalopram (10mg). All participants will also be followed by their Buprenorphine clinic medical provider. Questions during the face-to-face interviews will assess mood, drug craving, pain, sleep, medication adherence and drug-related experiences. Comparison(s): Participants randomized into the medication component of the study as compared to participants randomized into the placebo component of the study.

Conditions

• Opiate Dependence
• Depression

Interventions

Type	Name	Description
DRUG	escitalopram	10mg escitalopram/day for 3 months
DRUG	placebo	placebo capsule/day for 3 months

Timeline

• Start date: 2006-12-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2007-05-21
• Last updated: 2012-04-03
• Results posted: 2012-04-03

Locations

1 site across 1 country: United States